Scientists from Rockefeller University have demonstrated in laboratory research on mice that anti-inflammatory drugs reduce the effectiveness of commonly used antidepressant medications.
Paul Greengard, Ph.D., and Jennifer Warner-Schmidt, Ph.D., discovered commonly used medications such as ibuprofen, aspirin and naproxen reduce the benefits of selective serotonin reuptake inhibitors (SSRIs) including fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox) and citalopram (Celexa).
According to the researchers, this discovery may explain why so many depressed patients taking SSRIs do not respond to treatment and that this lack of effectiveness may be preventable.
The research is published in the journal Proceedings of the National Academy of Sciences.
Experts believe the study may be especially significant in the case of Alzheimer’s disease. Such patients commonly suffer from depression and unless this can be treated successfully, the course of the illness is likely to be more severe.
Depression in the elderly is also a risk factor for developing Alzheimer’s disease, and researchers have suggested that treating depression in the elderly might reduce the risk of developing the disease.
In the recent study, investigators treated mice with antidepressants in the presence or absence of anti-inflammatory drugs. They then examined how the mice behaved in tasks that are sensitive to antidepressant treatment. The behavioral responses to antidepressants were inhibited by anti-inflammatory/analgesic treatments.
They then confirmed these effects in a human population. Depressed individuals who reported anti-inflammatory drug use were much less likely to have their symptoms relieved by an antidepressant than depressed patients who reported no anti-inflammatory drug use.
The effect was rather dramatic since, in the absence of any anti-inflammatory or analgesic use, 54 percent of patients responded to the antidepressant, whereas success rates dropped to approximately 40 percent for those who reported using anti-inflammatory agents.
“The mechanism underlying these effects is not yet clear. Nevertheless, our results may have profound implications for patients, given the very high treatment resistance rates for depressed individuals taking SSRIs,” said Warner-Schmidt.
Greengard added, “Many elderly individuals suffering from depression also have arthritic or related diseases and as a consequence are taking both antidepressant and anti-inflammatory medications.
“Our results suggest that physicians should carefully balance the advantages and disadvantages of continuing anti-inflammatory therapy in patients being treated with antidepressant medications.”
Source: Rockefeller University